Effects of Triple Therapy on the Clinical Course of Non-Eosinophilic COPD Groups B
Journal of Korean Medical Science · 2025 · 40 (28)
DOI: 10.3346/jkms.2025.40.e147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Korean Medical Science, 2025. Verfasst von Jin Hwa Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Veteran Health Service Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Muscarinic Antagonists, Adrenergic beta-2 Receptor Agonists, Adrenal Cortex Hormones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea National Institute of Health.
Themen: COPD
Abstract (Originalsprache)
BACKGROUND: Although the efficacy of triple therapy in treating chronic obstructive pulmonary disease (COPD) patients with a history of exacerbation is well established in groups with frequent exacerbations, less research has been conducted on its use in group B. Here, we investigated the effects of triple therapy on COPD patients with low eosinophil counts in the context of the current management of group B. METHODS: Using data from the Korean COPD Subtype Study (KOCOSS), we selected patients with blood eosinophil count (BEC) less than 300 cells/μL as non-eosinophilic COPD groups. The study evaluated the effect of a triple therapy group (combination of inhaled corticosteroid, a long-acting β2-agonist [LABA] and a long-acting muscarinic antagonist [LAMA]) and a dual therapy group (LABA/LAMA) on moderate-to-severe exacerbations, as well as longitudinal changes in lung function over 3 years in patients categorized as Global Initiative for Chronic Obstructive Lung Disease (GOLD) B. RESULTS: Of the 328 non-eosinophilic COPD group B, 145 (44.2%) patients were in triple therapy and 183 (55.8%) patients were in dual therapy. Triple therapy group showed an increased risk of moderate-to-severe exacerbation in multivariate adjusted model (adjusted incidence rate ratio of annual rate, 2.04; 95% confidence interval, 1.45 to 2.84; P < 0.001). Similarly, restricted cubic spline regression analysis of annual rates of moderate-to-severe exacerbations suggested an increased risk associated with the triple therapy over dual therapy in BEC lower than 300 cells/μL. There was no significant difference in the adjusted rate of forced expiratory volume in 1 second decline between triple therapy group and dual therapy group (-10.0 [-39.8 to -19.7] mL/year vs. 22.3 [-4.4 to -49.0] mL/year, P for interaction = 0.888). CONCLUSION: In conclusion, our research suggests that triple therapy was associated with a higher risk of moderate-to-severe exacerbations in non-eosinophilic COPD categorized as GOLD B compared with dual therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Veteran Health Service Medical Center, Seoul, Korea.
- Division of Allergy and Pulmonary Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
- Division of Pulmonology and Allergy, Department of Internal Medicine, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu, Korea.
- Division of Pulmonary and Allergy, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.
- Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, Korea.
ORCID-Profile: Jin Hwa Song, Shinhee Park, Jong Geol Jang, Youlim Kim, Seung Won Ra, Chang Youl Lee, Deog Kyeom Kim, Hyoung Kyu Yoon, Kwang Ha Yoo, Hee Joung Kim
Förderung
- Korea National Institute of Health
Zitieren
APA
Song, J. H., Park, S., Jang, J. G., Kim, Y., Ra, S. W., Lee, C. Y., Kim, D. K., Yoon, H. K., Yoo, K. H., & Kim, H. J. (2025). Effects of Triple Therapy on the Clinical Course of Non-Eosinophilic COPD Groups B. Journal of Korean Medical Science, 40(28). https://doi.org/10.3346/jkms.2025.40.e147
Vancouver
Song JH, Park S, Jang JG, Kim Y, Ra SW, Lee CY, et al. Effects of Triple Therapy on the Clinical Course of Non-Eosinophilic COPD Groups B. Journal of Korean Medical Science. 2025;40(28). doi:10.3346/jkms.2025.40.e147
BibTeX
@article{Song2025,
author = {Song, Jin Hwa and Park, Shinhee and Jang, Jong Geol and Kim, Youlim and Ra, Seung Won and Lee, Chang Youl and Kim, Deog Kyeom and Yoon, Hyoung Kyu and Yoo, Kwang Ha and Kim, Hee Joung},
title = {Effects of Triple Therapy on the Clinical Course of Non-Eosinophilic COPD Groups B},
journal = {Journal of Korean Medical Science},
year = {2025},
volume = {40},
number = {28},
doi = {10.3346/jkms.2025.40.e147}
}
EUVIMED